Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176144
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Solanich, Xavier | - |
dc.contributor.author | Fernández Huerta, Miguel | - |
dc.contributor.author | Basaez, Celeste | - |
dc.contributor.author | Antolí, Arnau | - |
dc.contributor.author | Rocamora Blanch, Gemma | - |
dc.contributor.author | Corbella, Xavier | - |
dc.contributor.author | Santín Cerezales, Miguel | - |
dc.contributor.author | Alcaide Fernández de Vega, Fernando | - |
dc.date.accessioned | 2021-04-09T13:28:05Z | - |
dc.date.available | 2021-04-09T13:28:05Z | - |
dc.date.issued | 2021-02-26 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176144 | - |
dc.description.abstract | Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19 patients. Our aim was to determine the prevalence and the factors related to an indeterminate QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay was performed in a tertiary care public hospital during the first epidemic wave in Spain (March-April 2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002-1.008]) and previous administration of corticosteroids (OR 4.477 [95% CI 1.397-14.345]), were independent predictors for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm10050918 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2021, vol. 10, num. 5, p. 918 | - |
dc.relation.uri | https://doi.org/10.3390/jcm10050918 | - |
dc.rights | cc-by (c) Solanich, Xavier et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Mortalitat | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Mortality | - |
dc.title | Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 708514 | - |
dc.date.updated | 2021-04-09T13:28:05Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33652893 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
708514.pdf | 467.97 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License